UBS Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-923
| Closed | -$3.62K | – | 10565 |
|
|
2023
Q3 | $3.62K | Buy |
923
+663
| +255% | +$4.53K | ﹤0.01% | 7534 |
|
|
2023
Q2 | $845 | Sell |
260
-140
| -35% | -$416 | ﹤0.01% | 8085 |
|
|
2023
Q1 | $1.45K | Buy |
400
+172
| +75% | +$2.65K | ﹤0.01% | 8739 |
|
|
2022
Q4 | $7.35K | Buy |
228
+97
| +74% | +$3.84K | ﹤0.01% | 8905 |
|
|
2022
Q3 | $5K | Buy |
+131
| New | +$5.99K | ﹤0.01% | 9279 |
|
|
2022
Q1 | – | Sell |
-629
| Closed | -$76K | – | 11258 |
|
|
2021
Q4 | $76K | Buy |
629
+572
| +1,004% | +$96.6K | ﹤0.01% | 6545 |
|
|
2021
Q3 | $8K | Sell |
57
-70
| -55% | -$13.9K | ﹤0.01% | 8251 |
|
|
2021
Q2 | $35K | Sell |
127
-49
| -28% | -$12.4K | ﹤0.01% | 6782 |
|
|
2021
Q1 | $38K | Sell |
176
-43
| -20% | -$11.9K | ﹤0.01% | 6810 |
|
|
2020
Q4 | $53K | Buy |
219
+158
| +259% | +$19.5K | ﹤0.01% | 6139 |
|
|
2020
Q3 | $6K | Sell |
61
-175
| -74% | -$15.9K | ﹤0.01% | 7255 |
|
|
2020
Q2 | $23K | Sell |
236
-166
| -41% | -$14.5K | ﹤0.01% | 6477 |
|
|
2020
Q1 | $30K | Sell |
402
-452
| -53% | -$43K | ﹤0.01% | 6220 |
|
|
2019
Q4 | $69K | Buy |
854
+201
| +31% | +$22.5K | ﹤0.01% | 6190 |
|
|
2019
Q3 | $80K | Buy |
653
+470
| +257% | +$64.6K | ﹤0.01% | 5905 |
|
|
2019
Q2 | $33K | Buy |
183
+174
| +1,933% | +$28.1K | ﹤0.01% | 6272 |
|
|
2019
Q1 | $2K | Sell |
9
-319
| -97% | -$63.2K | ﹤0.01% | 7483 |
|
|
2018
Q4 | $85K | Buy |
328
+222
| +209% | +$44.7K | ﹤0.01% | 5672 |
|
|
2018
Q3 | $26K | Buy |
106
+75
| +242% | +$19.6K | ﹤0.01% | 6644 |
|
|
2018
Q2 | $7K | Buy |
+31
| New | +$9.04K | ﹤0.01% | 7361 |
|
Other funds holding EVLO
UBS Group's EVLO Position: Q4 2023 in Review
UBS Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 923 shares — an estimated $3.62K sold.
UBS Group first reported a position in EVLO in Q2 2018 and held it in 20 quarters. The position peaked at $85K in Q4 2018. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- UBS Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- UBS Group sold 923 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $3.62K.
- UBS Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 20 quarters.
- UBS Group's Evelo Biosciences, Inc. Common Stock position peaked at $85K in Q4 2018.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.